



[www.cegog.org](http://www.cegog.org)

# 9th CECOG PANCREAS AND CHOLANGIOCELLULAR CANCERS ACADEMY

**20–21 June, 2025**

**Josephinum,  
Währinger Str. 25,  
1090 Wien, Austria**

## **Scientific Committee**

Gerald Prager (Austria)  
Christoph Zielinski (Austria)  
Christiane Thallinger (Austria)

## THE CECOG PRESIDENCY

All related educational events are clearly identifiable as part of the CECOG Academy and are therefore known for the high quality of the educational content.



### Univ. Professor Dr. Dr.h.c. Christoph Zielinski

Director of the Central European Cancer Center and Medical Director at Wiener Privatklinik, Vienna, Austria, and President of CECOG; he was previously chairing the Vienna Cancer Center, the Clinical Division of Oncology, the Department of Medicine I and the Comprehensive Cancer Center at Medical University Vienna and the General Hospital in Vienna, Austria; he achieved his training in basic and clinical immunology, internal medicine and medical oncology at the University of Vienna, Austria, and at the Cancer Research Center at Tufts University, Boston, Mass. USA; he is member of the European Society for Medical Oncology, served on its Executive Committee and Council and as Editor in Chief of the society's peer-review journal "ESMO Open-Cancer Horizons" from 2016-2023. He published over 630 original scientific papers and reviews in peer-reviewed journals, and many books. His h-index is 82 and the citations of scientific papers authored by him exceed 35.000.



### Priv. Doz. Dr. Christiane Thallinger, MSc, MBA

Priv. Doz. Doctor Christiane Thallinger is a registered senior consultant in dermatology and venerology and Program Director of Chemotherapy-Related Skin Side Effects at the Department of Medicine I at the Medical University and the General Hospital (AKH), Vienna, Austria. In addition, she works as a Clinical Trials Physician at CECOG. Doctor Thallinger completed her medical training at the University Hospital Vienna. After finishing her training in dermatology and venerology at the medical university of Vienna, she worked as a postdoctoral fellow at the University of San Diego, California (UCSD), USA focusing on psoriasis and skin cancer. Ever since her return to Medical University of Vienna and the General Hospital (AKH), Doctor Thallinger's main focus consisted in diagnosis and treatment of skin cancer and related side effects occurring on the skin. Her clinical experience covers a wide range of dermatology with focus on melanoma and "white" skin cancer, as well as chemotherapy induced skin side effects. She has published results over 66 original investigations and reviews in peer-review journals. She is a member of the European Society for Medical Oncology (ESMO) and the Austrian Society of Dermatology (ÖGDV).

## The CECOG Advisory Board

The CECOG Advisory Board is comprised of esteemed professors, scientists, and physicians representing diverse specialities and various geographic regions across Central and Southeastern Europe. These distinguished experts contribute their wealth of knowledge and experience to shape the scientific programs of CECOG Academies, ensuring relevance, innovation, and excellence in Continuing Medical Education in the interdisciplinary field of oncology.

The CECOG Board of Advisors consists of the following experts:

- Rupert Bartsch, AT
- Piotr Wysocki, PL
- Manuela Schmidinger, AT
- Gerald Prager, AT
- Tanja Cufer, SI
- Jacek Jassem, PL
- Cornelia Nitipir, RO
- Luka Brcic, AT
- Mir Alireza Hoda, AT
- Marko Jakopovic, HR
- Jelena Spasic, RS
- Rosi Ruseva, BG
- Sebastian Schoppmann, AT

**SCIENTIFIC PROGRAMME | Friday, 20 June, 2025****Opening & Key-Note**

Welcome Words by

**Dr. Gerald Prager**

Medical University of Vienna, Austria



**Dr. Christoph Zielinski**

Wiener Privatklinik, Vienna, Austria



Keynote: Treatment of Pancreatic Cancer: Advances and Drawbacks

**Dr. Gerald Prager**

Medical University of Vienna, Austria

**Metastatic Pancreas Cancer (PC)**

Which Chemotherapy Combination and for Whom?

Experimental and Developing Treatment Options

**Dr. Michel Ducreux**

Gustave Roussy Institute,  
Villejuif, France



Second Line Treatment of Metastatic PC

**Dr. Gerald Prager**

Medical University of Vienna, Austria



First Line Treatment of Metastatic PC

**Dr. Teresa Macarulla**

University Hospital Vall d'Hebron,  
Barcelona, Spain



Neuroendocrine PC: Which Drugs and When

**Dr. Julien Taieb**

Paris Cité University, France



Coffee Break 15:15 – 15:45

**Understanding Pancreas Cancer (PC)**

What are the Hypotheses Regarding the Underlying Biology of PC

**Dr. Michel Ducreux**

Gustave Roussy Institute,  
Villejuif, France



Molecular Diagnostics – to Which Avail?

**Dr. Arndt Vogel**

Hannover Medical School, Germany



Radiologic Diagnostic Options in Early and Metastatic PC

**Dr. Helmut Ringl**

Medical University of Vienna, Austria



Welcome Reception at the Josephinum 17:15 – 18:30

**SCIENTIFIC PROGRAMME | Saturday, 21 June, 2025****Coffee Break 8:30 – 9:30****Neoadjuvant Therapy of PC**

9:30 – 11:00

Patient Selection for Upfront Surgical Resection of PC

**Dr. Thilo Hackert**University Medical Center  
Hamburg-Eppendorf, Germany

Patient Selection for Neoadjuvant Chemotherapy &amp; Selecting the Optimal Chemotherapy Combination

**Dr. Davide Melisi**Medical School and University  
Hospital, Verona, Italy

Is there a Place for Radiotherapy?

**Dr. Mariano Ponz Sarvisé**Universidad de Navarra,  
Pamplona, Spain**Coffee Break 11:00 – 11:30****Diagnostic and Therapeutic Aspects in Cholangiocellular Cancer (CCC)**

11:30 – 13:30

Molecular Diagnostics – What to Look for and When

**Dr. Teresa Macarulla**University Hospital Vall d'Hebron,  
Barcelona, Spain

Surgical Treatment of CCC – When to Intervene and With Which Benefit

**Dr. Thilo Hackert**University Medical Center  
Hamburg-Eppendorf, Germany

Perioperative Treatment Options

**Dr. Davide Melisi**Medical School and University  
Hospital, Verona, Italy

Treatment of Advanced CCC – Molecular Targeted Therapy Versus Immune Checkpoint Inhibitors

**Dr. Harpreet Wasan**Imperial College Healthcare NHS  
Trust, London, UK**Adjourn**